Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:4:p11
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 4 (pt 11/22)
Character Range: 213684–217070

except when included in Schedule 2 or Schedule 3.
HYOSCYAMUS NIGER except:
 (a) when included in Schedule 2; or
 (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBOGAINE.
IBRITUMOMAB.
IBRUTINIB.
IBUFENAC.
IBUPROFEN except when:
 (a) included in Schedule 2 or 3; or
 (b) in preparations for dermal use; or
 (c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

          (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

          (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

          (iii) in a primary pack containing not more than 25 dosage units; and

          (iv) compliant with the requirements of the required advisory statements for medicine labels; and

          (v) not labelled for the treatment of children 6 years and under; and

          (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.
# IBUTAMOREN.
IBUTEROL.
IBUTILIDE.
ICATIBANT.
IDARUBICIN.
IDARUCIZUMAB.
IDEBENONE.
IDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMDEVIMAB.
IMEPITOIN.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENEM.
IMIPRAMINE.
IMIQUIMOD.
IMLIFIDASE.
IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.
INCLISIRAN.
INDACATEROL.
INDAPAMIDE.
INDINAVIR.
INDOMETACIN except when included in Schedule 2.
INDOPROFEN.
INDORAMIN.
INEBILIZUMAB.
INFIGRATINIB.
INFLIXIMAB.
INFLUENZA AND CORYZA VACCINES:
 (a) for parenteral use; or
 (b) for nasal administration.
INGENOL MEBUTATE.
INOTUZUMAB OZOGAMICIN.
INSULIN DEGLUDEC.
INSULIN GLARGINE.
# INSULIN‑LIKE GROWTH FACTOR I.
# INSULIN‑LIKE GROWTH FACTORS except when separately specified in this Schedule.
INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL.
# IPAMORELIN.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IPTACOPAN.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use.
ISAVUCONAZOLE.
ISOAMINILE.
ISOAMYL NITRITE.
ISOBUTYL NITRITE.
ISOCARBOXAZID.
ISOCONAZOLE except when included in Schedule 2, 3 or 6.
ISOETARINE.
ISOFLURANE for therapeutic use.
ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE except when included in Schedule 2.
ISOSORBIDE DINITRATE except when included in Schedule 3.
ISOSORBIDE MONONITRATE.
# ISOTRETINOIN.
ISOXICAM.
ISOXSUPRINE.
ISRADIPINE.
ITRACONAZOLE.
IVABRADINE.
IVACAFTOR.
IVERMECTIN:
 (a) for human use; or
 (b) for the treatment of mange in dogs.
IVOSIDENIB.
IXABEPILONE.
IXAZOMIB.
IXEKIZUMAB.
JAPANESE ENCEPHALITIS VACCINE.
KANAMYCIN.
KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.
# KETAZOLAM.
KETOCONAZOLE except:
 (a) when included in Schedule 2; or
 (b) in preparations for dermal use containing 1% or less of ketoconazole for the